CAD manipulates tumor intrinsic DHO/UBE4B/NF-κB pathway and fuels macrophage cross-talk, promoting HCC metastasis
- PMID: 40073276
- DOI: 10.1097/HEP.0000000000001304
CAD manipulates tumor intrinsic DHO/UBE4B/NF-κB pathway and fuels macrophage cross-talk, promoting HCC metastasis
Abstract
Background and aims: Portal vein tumor thrombosis (PVTT), an indicator of clinical metastasis, significantly shortens the lifespan of patients with HCC, and no effective treatment has been established. We aimed to illustrate the mechanisms underlying PVTT formation and tumor metastasis and identify potential targets for clinical intervention.
Approach and results: Multi-omics data of 159 patients with HCC (including 37 cases with PVTT) was analyzed to identify contributors to PVTT formation and tumor metastasis. In vitro and in vivo experiments were performed to confirm the critical role of carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) in HCC metastasis. Metabolomics and transcriptomics techniques, single-cell RNA sequencing, combined with experimental verification, were complemented to illustrate mechanisms underlying CAD-induced pro-metastatic efficacy. Analysis of proteogenomic data of HCC cohort identified CAD as the key contributor to PVTT formation and tumor metastasis in HCC. Further experiments confirmed that high CAD expression could significantly promote HCC metastasis, and vice versa. Mechanistically, CAD manipulated de novo pyrimidine anabolism, leading to dihydroorotic acid (DHO) accumulation, which is directly bound to ubiquitination factor E4B (UBE4B). UBE4B subsequently regulated JAK1 ubiquitination and activated the NF-κB pathway to promote epithelial-mesenchymal transition of HCC cells. In addition, CAD generated an immunosuppressive milieu conducive to HCC metastasis by recruiting and reprogramming macrophages into a "pro-tumor" phenotype. Consequently, the metastatic capability of HCC was remarkably enhanced.
Conclusions: Therapy targeting CAD may offer a promising approach to curb HCC metastasis by reducing tumor cells' metastatic potential and also shifting the tumor microenvironment toward a less pro-metastatic state.
Keywords: CAD; HCC; UBE4B; dihydroorotic acid; macrophage; metastasis.
Copyright © 2025 American Association for the Study of Liver Diseases.
References
-
- Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 2024;21:294–311.
-
- Wang JC, Xia AL, Xu Y, Lu XJ. Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. J Cell Physiol. 2019;234:1062–1070.
-
- Zhou XH, Li JR, Zheng TH, Chen H, Cai C, Ye SL, et al. Portal vein tumor thrombosis in hepatocellular carcinoma: Molecular mechanism and therapy. Clin Exp Metastasis. 2023;40:5–32.
-
- Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10:99–111.
-
- Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet. 2012;44:1117–1121.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
